GlassScriptPhysician profile
Julianne J Oboyle
NPI 1750376182
$11,113.92
in general payments reported to CMS, 2019-2025
53 companies · $2,879 in 2025
The $2,879 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $667 · 2021: $1,358 · 2022: $1,467 · 2023: $1,560 · 2024: $2,365 · 2025: $2,879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,762 · Education: $41.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,762.14 |
| Education | $41.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,272.57 | 2019-2025 | |
| Biogen, INC. | $1,195.31 | 2019-2025 | Vumerity, Leqembi, Tysabri |
| Alexion Pharmaceuticals, INC. | $1,161.52 | 2019-2025 | Ultomiris, Soliris |
| Abbvie INC. | $748.42 | 2021-2025 | |
| Emd Serono, INC. | $499.46 | 2019-2025 | Mavenclad, Mavenclad |
| Ucb, INC. | $450.56 | 2024-2025 | Briviact, Rystiggo, Nayzilam |
| Eisai INC. | $426.83 | 2021-2025 | |
| Amgen INC. | $402.09 | 2019-2025 | Uplizna |
| Pfizer INC. | $388.69 | 2023-2025 | |
| Kyowa Kirin, INC. | $362.35 | 2019-2024 | Nourianz |
| Lilly USA, LLC | $342.48 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Janssen Pharmaceuticals, INC | $324.40 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $315.20 | 2020-2025 | Ingrezza, Ongentys |
| Celgene Corporation | $267.74 | 2021-2025 | Zeposia |
| Tg Therapeutics, INC. | $236.79 | 2024-2025 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $213.68 | 2020-2024 | Zeposia |
| Lundbeck LLC | $208.04 | 2022-2024 | Vyepti, Rexulti |
| Alnylam Pharmaceuticals INC. | $201.29 | 2025 | Amvuttra, Onpattro |
| Acadia Pharmaceuticals INC | $168.98 | 2023-2025 | Nuplazid |
| Biohaven Pharmaceuticals, INC. | $162.32 | 2021 | |
| Argenx US, INC. | $145.06 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Supernus Pharmaceuticals, INC. | $143.60 | 2019-2020 | |
| Sk Life Science, INC. | $142.91 | 2023-2025 | Xcopri |
| Genentech USA, INC. | $126.15 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Otsuka America Pharmaceutical, INC. | $107.99 | 2024-2025 | Rexulti |
| Mdd US Operations, LLC | $107.87 | 2024-2025 | Gocovri, Apokyn |
| Teva Pharmaceuticals USA, INC. | $105.47 | 2019-2022 | |
| Avion Pharmaceuticals | $90.06 | 2022 | |
| Vanda Pharmaceuticals INC. | $83.68 | 2025 | Ponvory |
| Axsome Therapeutics, INC. | $71.50 | 2025 | Symbravo |
| Biohaven Pharmaceutical Holding Company LTD. | $58.64 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $52.67 | 2020-2025 | |
| Ani Pharmaceuticals, INC. | $41.97 | 2025 | Purified Cortrophin Gel |
| Myriad Genetic Laboratories, INC. | $41.64 | 2021-2025 | Myrisk |
| Davol INC. | $40.42 | 2024-2025 | Phasix Mesh, Ventralight St |
| Neurelis, INC. | $36.83 | 2025 | Valtoco |
| Medtronic, INC. | $35.83 | 2025 | Transorb, Venaseal |
| Olympus America INC. | $33.75 | 2024 | Olympus, Endoeye Flex Deflectable Videoscope |
| Sunovion Pharmaceuticals INC. | $28.49 | 2021 | |
| Kci USA, INC. | $28.33 | 2019 | |
| Adamas Pharmaceuticals, INC. | $26.67 | 2019-2020 | |
| Livanova USA, INC. | $25.78 | 2019 | |
| Allergan, INC. | $21.10 | 2019 | |
| Horizon Therapeutics Plc | $20.91 | 2023 | Uplizna |
| Portola Pharmaceuticals, LLC | $19.81 | 2019 | |
| W. L. Gore & Associates, INC. | $18.78 | 2024 | Gore Synecor Biomaterial |
| Conmed Corporation | $18.63 | 2023 | Airseal |
| Impel Pharmaceuticals INC. | $17.74 | 2023 | Trudhesa |
| Baudax Bio INC. | $16.99 | 2020 | |
| Grifols USA, LLC | $16.16 | 2024 | Gamunex-C |
| Avanir Pharmaceuticals, INC. | $14.98 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.97 | 2020 | |
| Genzyme Corporation | $11.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julianne Oboyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.